Kyverna Therapeutics (KYTX) Total Current Liabilities (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Total Current Liabilities data on file, last reported at $29.7 million in Q1 2026.

• Quarterly Total Current Liabilities fell 10.87% year-over-year to $29.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.7 million (down 10.87% YoY) and the FY2025 annual result came in at $36.5 million, up 8.09% from the prior year.
• Total Current Liabilities retreated to $29.7 million in Q1 2026, from $36.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $39.8 million in Q2 2025 to a low of $19.9 million in Q4 2023.
• A 4-year average of $30.3 million and a median of $32.1 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Current Liabilities soared 69.98% — and 2026, when it fell 10.87%.
• Tracing KYTX's Total Current Liabilities over 4 years: stood at $19.9 million in 2023, then soared by 69.98% to $33.8 million in 2024, then increased by 8.09% to $36.5 million in 2025, then retreated by 18.67% to $29.7 million in 2026.
• The last three Total Current Liabilities figures came in at $29.7 million (Q1 2026), $36.5 million (Q4 2025), and $33.9 million (Q3 2025), per Business Quant data.